Amgen has unveiled its cutting-edge drug substance manufacturing facility in Holly Springs, North Carolina, marking a significant expansion of its U.S. production capabilities with a total investment of $1.5 billion. The company simultaneously announced an additional $1 billion investment to further expand the site, demonstrating its commitment to strengthening domestic pharmaceutical manufacturing.
The state-of-the-art facility, located in the heart of North Carolina's Research Triangle at Camp Helix Innovation Park, will span over 500,000 square feet across two drug substance facilities. The manufacturing complex represents a major advancement in sustainable pharmaceutical production, incorporating innovative hybrid technology that combines single-use systems with traditional stainless steel-fed batch processes.
Advanced Sustainable Manufacturing Design
The facility's innovative design achieves significant environmental benefits, reducing water consumption by 50% compared to conventional manufacturing plants. This efficiency aligns with Amgen's ambitious environmental goals, including achieving carbon neutrality by 2027. The reduced physical footprint of the facility demonstrates how modern manufacturing technology can maximize production capacity while minimizing environmental impact.
Strategic Location and Economic Impact
"We chose Holly Springs because the Research Triangle area offers unbeatable advantages, including a welcoming investment climate, a thriving innovation ecosystem and a diverse and skilled workforce," stated Amgen CEO Bob Bradway. The facility's location in the Research Triangle positions it within one of America's premier life sciences hubs.
The economic impact on the region will be substantial, with initial operations creating 350 full-time positions. This workforce will expand to 700 employees by 2030, encompassing roles for engineers, quality professionals, and manufacturing associates. Notably, approximately 70% of current site employees are North Carolina residents, underscoring the project's contribution to local employment.
Manufacturing Capabilities and Patient Impact
The new facility will strengthen Amgen's ability to ensure consistent supply of vital medicines for patients with serious conditions, including heart disease and cancer. The manufacturing complex will leverage Amgen's advanced technological and operational expertise to facilitate efficient global distribution of life-saving therapies.
"This plant will further strengthen our ability to provide an uninterrupted supply of our medicines for patients suffering from heart disease, cancer and other serious illnesses," Bradway emphasized, highlighting the facility's crucial role in Amgen's global supply chain strategy.
